AXGN
Axogen, Inc.
Overview
Axogen designs and manufactures peripheral nerve repair products for surgeons treating traumatic and surgical nerve injuries.
Axogen, Inc is a Healthcare company operating in Medical Devices with a $2.31B market cap.
Most recent reported earnings: Q2 FY2026 (Aug 3, 2026).
20 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from SEC 10-K filing, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q4 FY2025Earnings2026-02-2419 Q&A exchanges
- Q3 FY2025Earnings2025-10-2920 Q&A exchanges
- Q2 FY2025Earnings2025-08-0520 Q&A exchanges
- Q1 FY2025Earnings2025-05-0933 Q&A exchanges
- Q4 FY2024Earnings2025-02-2524 Q&A exchanges
- Q3 FY2024Earnings2024-11-0916 Q&A exchanges
- Q2 FY2024Earnings2024-08-0822 Q&A exchanges
- Q1 FY2024Earnings2024-05-0213 Q&A exchanges
- Q4 FY2023Earnings2024-03-0523 Q&A exchanges
- Q3 FY2023Earnings2023-11-0713 Q&A exchanges
- Q2 FY2023Earnings2023-08-0719 Q&A exchanges
- Q1 FY2023Earnings2023-05-0920 Q&A exchanges
- Q4 FY2022Earnings2023-03-1425 Q&A exchanges
- Q3 FY2022Earnings2022-11-0810 Q&A exchanges
- Q2 FY2022Earnings2022-08-065 Q&A exchanges
- Q1 FY2022Earnings2022-05-079 Q&A exchanges
- Q4 FY2021Earnings2022-02-228 Q&A exchanges
- Q3 FY2021Earnings2021-11-038 Q&A exchanges
- Q2 FY2021Earnings2021-08-058 Q&A exchanges
- Q1 FY2021Earnings2021-05-097 Q&A exchanges
History
Earnings history
- Q2 FY20262026-08-03EPS— vs $-0.04—Rev— vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-03 | — | $-0.04 | — | — | — | — | EODHD |
Source: EODHD. AXGN reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks AXGN's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters but stock falls 80% of the time
SampleWhen a company consistently beats but the stock doesn't react, consensus is usually set too low or the buy-side number is materially above sell-side. Watch for guidance walk-downs ahead of the print.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2025 | $1.91 | $1.73 | +10.3% | +0.7% | +3.1% |
| Q4 FY2025 | $2.03 | $1.65 | +23.0% | +0.5% | +2.4% |
| Q3 FY2025 | $1.97 | $1.63 | +21.0% | -4.0% | -6.3% |
| Q2 FY2025 | $2.08 | $1.73 | +20.3% | -7.1% | -5.4% |
| Q1 FY2024 | $2.08 | $1.80 | +15.5% | -1.8% | -0.1% |
| Q4 FY2024 | $2.24 | $1.83 | +22.6% | -6.8% | -4.9% |
| Q3 FY2024 | $2.03 | $1.70 | +19.2% | -7.4% | -4.9% |
| Q2 FY2024 | $1.82 | $1.64 | +11.1% | -0.9% | +1.2% |
| Q1 FY2023 | $2.27 | $1.94 | +16.9% | -2.6% | -5.2% |
| Q4 FY2023 | $2.17 | $1.75 | +24.2% | -3.5% | -3.0% |
Guidance change history
Sample- Q1 FY2025Raised2025-04-15
- Q4 FY2025Raised2025-13-15
- Q3 FY2025Raised2025-10-15
- Q2 FY2025Raised2025-07-15
- Q1 FY2024Raised2024-04-15
- Q4 FY2024Raised2024-13-15
- Q3 FY2024Raised2024-10-15
- Q2 FY2024Raised2024-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Michael D DaleCEO6 mo6 callsCurrentSample
CEO since 2025 • 2/2 beats (100%) • last call held guidance Q3 FY2025
- Lindsey Marie HartleyCFO6 mono recorded callsCurrentSample
CFO since 2025 • 1/2 beats (50%) • last call held guidance Q3 FY2025
- Jens KempChief Marketing Officer6 mo2 callsCurrentSample
OTHER_C_SUITE since 2025 • 1/2 beats (50%) • last call held guidance Q2 FY2025
- Erick Wayne DevinneyChief Innovation Officer9 mono recorded callsCurrentSample
OTHER_C_SUITE since 2025 • 1/2 beats (50%) • last call held guidance Q1 FY2025
- Marc A BeganEVP & General Counsel6 mono recorded callsCurrentSample
DIVISION_HEAD since 2025 • 2/2 beats (100%) • guidance suspended Q2 FY2025
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for AXGN.
$ curl https://api.spokenalpha.com/v1/companies/AXGNFAQ
Frequently asked about AXGN
Where can I find Axogen, Inc.'s (AXGN) earnings call transcripts?
Spoken Alpha indexes AXGN's earnings call transcripts at https://spokenalpha.com/companies/AXGN. Each call links to attributed speakers and parsed analyst Q&A. Axogen, Inc.'s own investor relations page is at https://ir.axogeninc.com/.
When was Axogen, Inc.'s most recent earnings call?
Axogen, Inc. (AXGN) held its most recent earnings call on 2026-02-24, covering fiscal Q4 2025.
What sector is AXGN in?
Axogen, Inc. (AXGN) operates in the Healthcare sector (Medical Devices industry).